The Emerging Technology Portal: An Information Session with RA Capital

Do you have an idea or technology you are interested in commercializing? Have you ever considered starting a life science company? Join the Harvard Biotech Club for a discussion with Joel Batson, Scientific Project Coordinator at RA Capital Management. RA Capital is a crossover investment manager dedicated to evidence-based investing in public and private healthcare and life science companies. Joel is spearheading a new program called “the Portal”, an adaptive due diligence questionnaire allowing innovators to apply for funding and business planning assistance from RA Capital’s experienced investment team. RA Capital is currently seeking volunteers to beta test the Portal, based on a proposed idea or actual drug development program. Please attend the information session to learn more about RA Capital and how you can participate in the testing phase for the Portal.

When: April 10, 2017 from 5-6 PM

Where: TMEC 227, Harvard Medical School

Dinner will be provided. Please RSVP at and contact us at with any questions.


Joel Batson is a Science Project Coordinator with the Beyond Healthcare Team within the TechAtlas division of RA Capital Management. Joel’s primary responsibilities at RA Capital are to develop new tools to systematically evaluate developmental drugs and to assess orthogonal technologies that intersect with the healthcare industry.

Andrew Senesi is an associate with the Beyond Healthcare Team within the TechAtlas division of RA Capital Management. His primary responsibility is to identify and assess technologies within the healthcare industry to find new investment opportunities for the firm. His PhD research at Northwestern University focused on the development of DNA scaffold-based nanoparticle superlattices, in addition to nano-patterning bio-molecules for lab-on-a-chip applications. His postdoctoral work at Argonne National Lab involved small-angle X-ray scattering based characterization of nanoscale systems.